Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1144]

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Bladder cancer updates from the first half of 2024

Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo

Bladder cancer updates from the first half of 2024 ( Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo )

Patient expectations and shared decision making in aRCC

Prof Manuela Schmidinger and Prof Ernst Agneter

Patient expectations and shared decision making in aRCC ( Prof Manuela Schmidinger and Prof Ernst Agneter )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel...

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

ARV-766 well tolerated and shows promising clinical activity in metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

ASCO 2024: Latest in mRCC treatment

Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas...

ASCO 2024: Latest in mRCC treatment ( Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas Powles )

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive...

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer ( Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy )

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS...

Dr Christos Kyriakopoulos - University of Wisconsin Carbone Cancer Center...

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive mCRPC following docetaxel ( Dr Christos Kyriakopoulos - University of Wisconsin Carbone Cancer Center, Madison, USA )

Looking at real world evidence on PSA testing in prostate cancer

Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi

Looking at real world evidence on PSA testing in prostate cancer ( Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi )

Safety and quality of life assessment, how do they impact patient decision...

Prof Manuela Schmidinger and Dena Battle

Safety and quality of life assessment, how do they impact patient decision? KCCure survey – part B ( Prof Manuela Schmidinger and Dena Battle )

More from ecancer